Although anti-LAG3 monotherapy has generally demonstrated limited antitumor efficacy, the combination of anti-LAG3 and anti-PD-1 has demonstrated synergistic activity in tumor models, leading to the development of the first anti-LAG3 mAbs, relatlimab [100]. The gene discussed is LAG3; the disease is neoplasm.